Todd Asset Management LLC Invests $21.84 Million in DaVita Inc. $DVA

Todd Asset Management LLC purchased a new stake in shares of DaVita Inc. (NYSE:DVA) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 164,387 shares of the company’s stock, valued at approximately $21,842,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV lifted its holdings in shares of DaVita by 38.7% during the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock valued at $53,383,000 after purchasing an additional 104,554 shares during the last quarter. Nordea Investment Management AB increased its position in DaVita by 1.8% during the 3rd quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock valued at $37,864,000 after buying an additional 5,193 shares in the last quarter. Man Group plc raised its stake in DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after buying an additional 269,081 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after acquiring an additional 150,318 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC grew its stake in shares of DaVita by 49.1% in the second quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock worth $36,730,000 after acquiring an additional 84,859 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.6%

Shares of DaVita stock opened at $149.12 on Monday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $159.27. The company’s 50 day moving average is $117.71 and its 200 day moving average is $124.74. The company has a market cap of $9.96 billion, a price-to-earnings ratio of 15.05, a price-to-earnings-growth ratio of 0.52 and a beta of 0.99.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the prior year, the firm earned $2.24 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on DVA shares. UBS Group upped their price target on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Barclays lifted their target price on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Truist Financial set a $158.00 price target on shares of DaVita in a report on Thursday, February 5th. TD Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DaVita currently has a consensus rating of “Hold” and an average price target of $160.50.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.